Adherence of Hispanic / Latina Breast Cancer - Patients to Adjuvant Aromatase Inhibitors
This is an observational trial designed to assess prospectively the adherence rate to AIs among women with invasive breast cancer (stages I-III) currently receiving AI adjuvant therapy after standard local and systemic therapy. We will study adherence by administrating the 8-item Morisky Medication Adherence Scale (MMAS - 8).
Breast Cancer
Adherence rate per the 8-item Morisky Medication Adherence Scale (MMAS - 8)., Primary endpoint of this study is to determine the adherence rate (high, medium and low) through the MMAS-8 among early stage breast cancer patients being treated at Texas Tech University Health Sciences Center El Paso (TTUHSC EP) where the majority of the patients are of Hispanic origin., Every 6 months for up to 24 months
* Women with breast cancer seen at the Texas Tech Physicians Breast Care Center will be recruited during their routine follow-up visit with their medical oncologist.
* Post - menopausal women with histologically confirmed hormonal positive (ER and/or PR) invasive breast cancer stages I - III with no evidence of metastatic disease (M0).
* Patients must be on one of AI (steroidal or non-steroidal).
* Patient must have completed local treatment (surgery /radiation) and recovered from all side effects of chemotherapy and surgery.
* Patient must be able to complete a demographic and the MMAS - 8 questionnaires in English or Spanish.